Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.54 |
| ▸ | HMGCR | P04035 | 3/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979048 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL1050169 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL40510 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2802414 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL20293445 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2985078 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL740489 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL12680242 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL257132 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL29377936 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136965-A | Isolated polypeptide of targeted MPP8 protein and application thereof | 苏州系统医学研究所 | 2025-06-13 | — | — | CN | claimed |
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3893934-B1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-09-10 | — | — | EP | disclosed |
| CN-120136965-A | Isolated polypeptide of targeted MPP8 protein and application thereof | 苏州系统医学研究所 | 2025-06-13 | — | — | CN | disclosed |
| US-20250092067-A1 | APT1 and APT2 Inhibitors and Uses Thereof | CORNELL UNIVERSITY | 2025-03-20 | — | — | US | disclosed |
| US-20240392041-A1 | Site-Specific Crosslinking of Antibodies | LIFE TECHNOLOGIES CORP (US) | 2024-11-28 | — | — | US | disclosed |
| US-12071487-B2 | Site-specific crosslinking of antibodies | Life Technologies Corporation (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2017218891-A1 | SITE-SPECIFIC CROSSLINKING OF ANTIBODIES | Life Technologies Corporation (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2017-12-21 | — | — | US | disclosed |
| WO-2017053706-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-2396418-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEINS | Genentech, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093916-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEINS | GENENTECH, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093916-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEINS | GENENTECH, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203647-A1 | Chemical Reporters of Protein Acylation | THE ROCKEFELLER UNIVERSITY (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100189660-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN | GENENTECH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189660-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN | GENENTECH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189660-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN | GENENTECH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | HSD17B10 2060/4885CYP1A2 1218/4885CYP2D6 1334/4885 |
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | HSD17B10 2060/4885CYP1A2 1218/4885CYP2D6 1334/4885 |
| US-20100189660-A1 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN | FABP1, DBI, FABP4 | HSD17B10 263/4885CYP1A2 3346/4885CYP2D6 3861/4885 |
| US-20250092067-A1 | APT1 and APT2 Inhibitors and Uses Thereof | LYPLA2, LYPLA1, PPT1 | HSD17B10 750/4885CYP1A2 2886/4885CYP2D6 4399/4885 |
| US-20100203647-A1 | Chemical Reporters of Protein Acylation | ACOT7, ACAT2, AADAC | HSD17B10 325/4885CYP1A2 3759/4885CYP2D6 3851/4885 |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | HSD17B10 2060/4885CYP1A2 1218/4885CYP2D6 1334/4885 |
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | HSD17B10 2060/4885CYP1A2 1218/4885CYP2D6 1334/4885 |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | HAO2, AHR, HMOX1 | HSD17B10 841/4885CYP1A2 35/4885CYP2D6 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.